The A-List: The Trend-Shaping Series A Financings Of 2013
This article was originally published in Start Up
It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.
You may also be interested in...
With the launch of its Xpresys Lung test, Integrated Diagnostics joins the ranks of commercial molecular diagnostics companies offering tests to help physicians characterize suspicious tissue. But unlike other tests on the market and in development, the Xpresys Lung test is designed to be used early in the process – before a biopsy is even ordered.
Bay City Capital will back the PharmAkea with a $10 million Series A financing. Celgene also holds an undisclosed equity stake in the new company, under a three-year, $35 million R&D funding agreement with options to extend the arrangement or acquire the firm.
You know times are tough for medtech start-ups in the US when even a successful serial entrepreneur like Michael Lesh, MD, is told by VCs, “We love your idea, but….” Middle Peak Medical, Lesh’s new start-up in the mitral valve space, solved its problem with a Series A financing round involving European investors and by co-locating itself in Germany and the US.